Pliant Therapeutics, Inc. (PLRX) Tops Q2 EPS by 1c

Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.70), $0.01 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $1.21 million.

For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist